wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q39007500-689896F9-805D-425A-8978-6EBDB8786AFC
Q39007500-689896F9-805D-425A-8978-6EBDB8786AFC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39007500-689896F9-805D-425A-8978-6EBDB8786AFC
New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer.
P2860
Q39007500-689896F9-805D-425A-8978-6EBDB8786AFC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39007500-689896F9-805D-425A-8978-6EBDB8786AFC
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
eb5782971ea3ec2d8647b16e3205c3355bdb6c4a
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.